(Q37784796)

23 August 2017

Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder (English)

1 reference

attention deficit hyperactivity disorder

23 August 2017

0 references

1 reference

1 reference

1 reference

Gary Stiefel

1

1 reference

PubMed ID

20812768

23 August 2017

Frank M C Besag

series ordinal

2

1 reference

23 August 2017

1 October 2010

1 reference

23 August 2017

1 reference

23 August 2017

33

1 reference

23 August 2017

821-842

1 reference

23 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.2165/11536380-000000000-00000

23 August 2017

0 references

cites work

Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11536380-000000000-00000

Long-term methylphenidate therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder

21 January 2018

1 reference

12 December 2020

ADHD drugs and cardiovascular risk

1 reference

12 December 2020

Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting

1 reference

12 December 2020

Report of the Second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland

1 reference

12 December 2020

Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database

1 reference

12 December 2020

Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder

1 reference

12 December 2020

Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children

1 reference

12 December 2020

American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008.

1 reference

12 December 2020

Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Baseline values from the electrocardiograms of children and adolescents with ADHD

1 reference

12 December 2020

Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in

1 reference

12 December 2020

An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.

1 reference

12 December 2020

Stimulants and sudden death: what is a physician to do?

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.

1 reference

12 December 2020

Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Stimulant-drug therapy for attention-deficit disorder (with or without hyperactivity) and sudden cardiac death

1 reference

12 December 2020

ADHD drugs and cardiovascular risk

1 reference

12 December 2020

Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study

1 reference

12 December 2020

An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder

1 reference

12 December 2020

Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.

1 reference

12 December 2020

Increased blood pressure and atomoxetine

1 reference

12 December 2020

Cardiovascular effects of atomoxetine in children, adolescents, and adults

1 reference

12 December 2020

Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study.

1 reference

12 December 2020

Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Atomoxetine-induced electrocardiogram changes

1 reference

12 December 2020

Comparison of the clinical efficacy of twice-daily Ritalin and once-daily Equasym XL with placebo in children with Attention Deficit/Hyperactivity Disorder

1 reference

12 December 2020

Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.

1 reference

12 December 2020

Seizures and prolonged QTc with atomoxetine overdose

1 reference

12 December 2020

Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study

1 reference

12 December 2020

Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.

1 reference

12 December 2020

Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Measurement of the subjective effects of methylphenidate in 11- to 15-year-old children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

The British Child and Adolescent Mental Health Survey 1999: the prevalence of DSM-IV disorders

1 reference

12 December 2020

Children and adolescent exposures to atomoxetine hydrochloride reported to a poison control center

1 reference

12 December 2020

Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.

1 reference

12 December 2020

Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial.

1 reference

12 December 2020

Sudden death and use of stimulant medications in youths.

1 reference

12 December 2020

Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.

1 reference

12 December 2020

Attention deficit disorder and methylphenidate: a multi-step analysis of dose-response effects on children's cardiovascular functioning

1 reference

12 December 2020

Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders

1 reference

12 December 2020

New normal limits for the paediatric electrocardiogram

1 reference

12 December 2020

Methylphenidate-induced cardiac arrhythmias

1 reference

12 December 2020

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder

1 reference

12 December 2020

Short-term cardiovascular effects of methylphenidate and adderall

1 reference

12 December 2020

Relative cardiovascular safety of psychostimulants used to treat attention-deficit hyperactivity disorder

1 reference

12 December 2020

Hemodynamic effects of acute administration of atomoxetine and methylphenidate

1 reference

12 December 2020

Norepinephrine transporter blockade with atomoxetine induces hypertension in patients with impaired autonomic function

1 reference

12 December 2020

Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study

1 reference

12 December 2020

Attention-deficit hyperactivity disorder (ADHD) treatment and sudden death

1 reference

12 December 2020

Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management.

1 reference

12 December 2020

10.2165/11536380-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

20812768

Dimensions Publication ID

23 August 2017

0 references

1 reference

PubMed ID

20812768